Prevention of experimental autoimmune uveoretinitis by blockade of osteopontin with small interfering RNA

Experimental Eye Research

Volumn 90, Issue 1, 2010, Pages 41-48

  Iwata, Daiju ^a,b   Kitamura, Mizuki ^a,b   Kitaichi, Nobuyoshi ^b   Saito, Yoshinari ^a   Kon, Shigeyuki ^a   Namba, Kenichi ^b   Morimoto, Junko ^a   Ebihara, Akiko ^a,b   Kitamei, Hirokuni ^b   Yoshida, Kazuhiko ^b   Ishida, Susumu ^b   Ohno, Shigeaki ^b   Uede, Toshimitsu ^a   Onoé, Kazunori ^a   Iwabuchi, Kazuya ^a,b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

EAU; inflammation; OPN; RNA interference; uveitis

Indexed keywords

OSTEOPONTIN; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; DRUG MECHANISM; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; RNA INTERFERENCE; T LYMPHOCYTE; UVEORETINITIS;

ANIMALS; AUTOIMMUNE DISEASES; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; OSTEOPONTIN; RETINITIS; RNA INTERFERENCE; RNA, SMALL INTERFERING; T-LYMPHOCYTES; UVEITIS;

EID: 70749083915     PISSN: 00144835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exer.2009.09.008     Document Type: Article

References (52)

1. Agarwal R.K., Kang Y., Zambidis E., Scott D.W., Chan C.C., and Caspi R.R. Retroviral gene therapy with an immunoglobulin-antigen fusion construct protects from experimental autoimmune uveitis. J. Clin. Invest. 106 (2000) 245-252
2. Amadi-Obi A., Yu C.R., Liu X., Mahdi R.M., Clarke G.L., Nussenblatt R.B., Gery I., Lee Y.S., and Egwuagu C.E. TH17 cells contribute to uveitis and scleritis and are expanded by IL-2 and inhibited by IL-27/STAT1. Nat. Med. 13 (2007) 711-718
3. Ashkar S., Weber G.F., Panoutsakopoulou V., Sanchirico M.E., Jansson M., Zawaideh S., Rittling S.R., Denhardt D.T., Glimcher M.J., and Cantor H. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287 (2000) 860-864
4. Calder C.J., Nicholson L.B., and Dick A.D. A selective role for the TNF p55 receptor in autocrine signaling following IFN-γ stimulation in experimental autoimmune uveoretinitis. J. Immunol. 175 (2005) 6286-6293
5. Cantor H., and Shinohara M.L. Regulation of T-helper-cell lineage development by osteopontin: the inside story. Nat. Rev. Immunol. 9 (2009) 137-141
6. Caspi R.R. Th1 and Th2 responses in pathogenesis and regulation of experimental autoimmune uveoretinitis. Int. Rev. Immunol. 21 (2002) 197-208
7. Caspi R.R. Experimental autoimmune uveoretinitis in the rat and mouse. Curr. Protoc. Immunol. (2003) Chapter 15: Unit 15.6
8. Caspi R.R., Roberge F.G., Chan C.C., Wiggert B., Chader G.J., Rozenszajn L.A., Lando Z., and Nussenblatt R.B. A new model of autoimmune disease. Experimental autoimmune uveoretinitis induced in mice with two different retinal antigens. J. Immunol. 140 (1988) 1490-1495
9. Caspi R.R., Roberge F.G., McAllister C.G., el-Saied M., Kuwabara T., Gery I., Hanna E., and Nussenblatt R.B. T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J. Immunol. 136 (1986) 928-933
10. Chabas D., Baranzini S.E., Mitchell D., Bernard C.C., Rittling S.R., Denhardt D.T., Sobel R.A., Lock C., Karpuj M., Pedotti R., Heller R., Oksenberg J.R., and Steinman L. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294 (2001) 1731-1735
11. Comabella M., Pericot I., Goertsches R., Nos C., Castillo M., Blas Navarro J., Rio J., and Montalban X. Plasma osteopontin levels in multiple sclerosis. J. Neuroimmunol. 158 (2005) 231-239
12. Cook E.B., Stahl J.L., Lowe L., Chen R., Morgan E., Wilson J., Varro R., Chan A., Graziano F.M., and Barney N.P. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. J. Immunol. Methods 254 (2001) 109-118
13. Denhardt D.T., Noda M., O'Regan A.W., Pavlin D., and Berman J.S. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J. Clin. Invest. 107 (2001) 1055-1061
14. Diao H., Kon S., Iwabuchi K., Kimura C., Morimoto J., Ito D., Segawa T., Maeda M., Hamuro J., Nakayama T., Taniguchi M., Yagita H., Van Kaer L., Onoe K., Denhardt D., Rittling S., and Uede T. Osteopontin as a mediator of NKT cell function in T cell-mediated liver diseases. Immunity 21 (2004) 539-550
15. Diao H., Iwabuchi K., Li L., Onoé L., Van Kaer L., Kon S., Saito Y., Morimoto J., Denhardt D., Rittling S., and Uede T. Osteopontin regulates development and function of invariant natural killer T cells. Proc. Natl. Acad. Sci. USA 105 (2008) 15884-15889
16. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., and Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411 (2001) 494-498
17. Fukushima A., Yamaguchi T., Ishida W., Fukata K., Udaka K., and Ueno H. Mice lacking the IFN-gamma receptor or fyn develop severe experimental autoimmune uveoretinitis characterized by different immune responses. Immunogenetics 57 (2005) 337-343
18. Green E.A., and Flavell R.A. Tumor necrosis factor-α and the progression of diabetes in non-obese diabetic mice. Immunol. Rev. 169 (1999) 11-22
19. Gregerson D.S., Obritsch W.F., Fling S.P., and Cameron J.D. S-antigen-specific rat T cell lines recognize peptide fragments of S-antigen and mediate experimental autoimmune uveoretinitis and pinealitis. J. Immunol. 136 (1986) 2875-2882
20. Hannon G.J. RNA interference. Nature 418 (2002) 244-251
21. Hikita S.T., Vistica B.P., Jones H.R., Keswani J.R., Watson M.M., Ericson V.R., Ayoub G.S., Gery I., and Clegg D.O. Osteopontin is proinflammatory in experimental autoimmune uveitis. Invest. Ophthalmol. Vis. Sci. 47 (2006) 4435-4443
22. Hoey S., Grabowski P.S., Ralston S.H., Forrester J.V., and Liversidge J. Nitric oxide accelerates the onset and increases the severity of experimental autoimmune uveoretinitis through an IFN-γ-dependent mechanism. J. Immunol. 159 (1997) 5132-5142
23. Howard K.A., and Kjems J. Polycation-based nanoparticle delivery for improved RNA interference therapeutics. Expert Opin. Biol. Ther. 7 (2007) 1811-1822
24. Hur E.M., Youssef S., Haws M.E., Zhang S.Y., Sobel R.A., and Steinman L. Osteopontin-induced relapse and progression of autoimmune brain disease through enhanced survival of activated T cells. Nat. Immunol. 8 (2007) 74-83
25. Jansson M., Panoutsakopoulou V., Baker J., Klein L., and Cantor H. Cutting edge: attenuated experimental autoimmune encephalomyelitis in eta-1/osteopontin-deficient mice. J. Immunol. 168 (2002) 2096-2099
26. Jiang H.R., Lumsden L., and Forrester J.V. Macrophages and dendritic cells in IRBP-induced experimental autoimmune uveoretinitis in B10RIII mice. Invest. Ophthalmol. Vis. Sci. 40 (1999) 3177-3185
27. Kezuka T., Sakai J., Yokoi H., Takeuchi M., Okada A., Taguchi O., Usui M., and Mizuguchi J. Peptide-mediated suppression of experimental autoimmune uveoretinitis in mice: development of a peptide vaccine. Int. Immunol. 8 (1996) 1229-1235
28. Khoury M., Louis-Plence P., Escriou V., Noel D., Largeau C., Cantos C., Scherman D., Jorgensen C., and Apparailly F. Efficient new cationic liposome formulation for systemic delivery of small interfering RNA silencing tumor necrosis factor alpha in experimental arthritis. Arthritis Rheum. 54 (2006) 1867-1877
29. Kitamura M., Iwabuchi K., Kitaichi N., Kon S., Kitamei H., Namba K., Yoshida K., Denhardt D.T., Rittling S.R., Ohno S., Uede T., and Onoe K. Osteopontin aggravates experimental autoimmune uveoretinitis in mice. J. Immunol. 178 (2007) 6567-6572
30. Liu F., Song Y., and Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther. 6 (1999) 1258-1266
31. Luger D., Silver P.B., Tang J., Cua D., Chen Z., Iwakura Y., Bowman E.P., Sgambellone N.M., Chan C.C., and Caspi R.R. Either a Th17 or a Th1 effector response can drive autoimmunity: conditions of disease induction affect dominant effector category. J. Exp. Med. 205 (2008) 799-810
32. Maeda K., Takahashi K., Takahashi F., Tamura N., Maeda M., Kon S., Uede T., and Fukuchi Y. Distinct roles of osteopontin fragments in the development of the pulmonary involvement in sarcoidosis. Lung 179 (2001) 279-291
33. Mochizuki M., Kuwabara T., McAllister C., Nussenblatt R.B., and Gery I. Adoptive transfer of experimental autoimmune uveoretinitis in rats. Immunopathogenic mechanisms and histologic features. Invest. Ophthalmol. Vis. Sci. 26 (1985) 1-9
34. Nakamura H., Siddiqui S.S., Shen X., Malik A.B., Pulido J.S., Kumar N.M., and Yue B.Y. RNA interference targeting transforming growth factor-beta type II receptor suppresses ocular inflammation and fibrosis. Mol. Vis. 10 (2004) 703-711
35. Namba K., Ogasawara K., Kitaichi N., Morohashi T., Sasamoto Y., Kotake S., Matsuda H., Iwabuchi K., Iwabuchi C., Ohno S., and Onoe K. Amelioration of experimental autoimmune uveoretinitis by pretreatment with a pathogenic peptide in liposome and anti-CD40 ligand monoclonal antibody. J. Immunol. 165 (2000) 2962-2969
36. Ohno S., Nakamura S., Hori S., Shimakawa S., Kawashima H., Mochizuki M., Sugita S., Ueno S., Yoshizaki K., and Inaba G. Efficacy, safety, and pharmakokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J. Rheumatol. 31 (2004) 1362-1368
37. Ohshima S., Yamaguchi N., Nishioka K., Mima T., Ishii T., Umeshita-Sasai M., Kobayashi H., Shimizu M., Katada Y., Wakitani S., Murata N., Nomura S., Matsuno H., Katayama R., Kon S., Inobe M., Uede T., Kawase I., and Saeki Y. Enhanced local production of osteopontin in rheumatoid joints. J. Rheumatol. 29 (2002) 2061-2067
38. O'Regan A., and Berman J.S. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int. J. Exp. Pathol. 81 (2000) 373-390
39. Rittling S.R., Matsumoto H.N., McKee M.D., Nanci A., An X.R., Novick K.E., Kowalski A.J., Noda M., and Denhardt D.T. Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro. J. Bone Miner. Res. 13 (1998) 1101-1111
40. Saito Y., Kon S., Fujiwara Y., Nakayama Y., Kurotaki D., Fukuda N., Kimura C., Kanayama M., Ito K., Diao H., Matsui Y., Komatsu Y., Ohtsuka E., and Uede T. Osteopontin small interfering RNA protects mice from fulminant hepatitis. Hum. Gene Ther. 18 (2007) 1205-1214
41. Saoudi A., Kuhn J., Huygen K., de Kozak Y., Velu T., Goldman M., Druet P., and Bellon B. TH2 activated cells prevent experimental autoimmune uveoretinitis, a TH1-dependent autoimmune disease. Eur. J. Immunol. 23 (1993) 3096-3103
42. Sato I., Yamamoto N., Yamazaki H., Hashimoto S., Hino M., Sakai F., and Fujie A. Prevention of the cryptic epitope SLAYGLR within osteopontin does not influence susceptibility to Candida albicans infection. Antimicrob. Agents Chemother. 49 (2005) 3053-3055
43. Schiffelers R.M., Xu J., Storm G., Woodle M.C., and Scaria P.V. Effects of treatment with small interfering RNA on joint inflammation in mice with collagen-induced arthritis. Arthritis Rheum. 52 (2005) 1314-1318
44. Shinohara M.L., Jansson M., Hwang E.S., Werneck M.B., Glimcher L.H., and Cantor H. T-bet-dependent expression of osteopontin contributes to T cell polarization. Proc. Natl. Acad. Sci. USA 102 (2005) 17101-17106
45. Shinohara M.L., Lu L., Bu J., Werneck M.B., Kobayashi K.S., Glimcher L.H., and Cantor H. Osteopontin expression is essential for interferon-α production by plasmacytoid dendritic cells. Nat. Immunol. 7 (2006) 498-506
46. Silver P.B., Chan C.C., Wiggert B., and Caspi R.R. The requirement for pertussis to induce EAU is strain-dependent: B10.RIII, but not B10.A mice, develop EAU and Th1 responses to IRBP without pertussis treatment. Invest. Ophthalmol. Vis. Sci. 40 (1999) 2898-2905
47. Song E., Lee S.K., Wang J., Ince N., Ouyang N., Min J., Chen J., Shankar P., and Lieberman J. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat. Med. 9 (2003) 347-351
48. Taooka Y., Chen J., Yednock T., and Sheppard D. The integrin alpha9beta1 mediates adhesion to activated endothelial cells and transendothelial neutrophil migration through interaction with vascular cell adhesion molecule-1. J. Cell Biol. 145 (1999) 413-420
49. Thurau S.R., Chan C.C., Nussenblatt R.B., and Caspi R.R. Oral tolerance in a murine model of relapsing experimental autoimmune uveoretinitis (EAU): induction of protective tolerance in primed animals. Clin. Exp. Immunol. 109 (1997) 370-376
50. Xie F.Y., Woodle M.C., and Lu P.Y. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov. Today 11 (2006) 67-73
51. Yamamoto N., Sakai F., Kon S., Morimoto J., Kimura C., Yamazaki H., Okazaki I., Seki N., Fujii T., and Uede T. Essential role of the cryptic epitope SLAYGLR within osteopontin in a murine model of rheumatoid arthritis. J. Clin. Invest. 112 (2003) 181-188
52. Yumoto K., Ishijima M., Rittling S.R., Tsuji K., Tsuchiya Y., Kon S., Nifuji A., Uede T., Denhardt D.T., and Noda M. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc. Natl. Acad. Sci. USA 99 (2002) 4556-4561